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Abstract 
Adipose tissue is also a secretory organ producing active substances called adipokines. Some of them (apelin, resistin, adiponectin, leptin, 
chemerin, or visfatin) may play a role in the pathogenesis and course of respiratory diseases, e.g. COPD, asthma, pulmonary hyperten-
sion, or lung cancer. There are limited and conflicting data on the role of adipokines in asthma. It has been confirmed, however, that 
visfatin and leptin can be markers of inflammation in COPD. Elevated concentrations of leptin and resistin play a pro-inflammatory role 
in the development of cancer cachexia. The role of adipokines has also been demonstrated in pulmonary hypertension, and the apelin-
adiponectin axis disruption may exacerbate pulmonary hypertension. (Endokrynol Pol 2019; 70 (6): 504–441)
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Introduction 
Energy and insolating functions are not the only func-
tions of fat tissue. It is also a secretory organ producing 
active substances called adipokines (Tab. I). It takes 
part in hunger regulation and maintenance of meta-
bolic homeostasis, coordinates neuroendocrine and 
immunological functions, and is a place of steroid and 
thyroid hormones metabolism. White adipose tissue 
(WAT) participates in hormonal and inflammatory 
processes (through cardiovascular protection or neoan-
giogenesis). Functions of visceral adipose tissue (VAT) 
are different; it is located within organs (e.g. kidneys) 
and muscles, in the epicardium, and inside blood ves-
sels. It is responsible for local (in the epicardium) and 
generalised inflammation, and — in muscles — for 
insulin resistance. Intravascular WAT affects the de-
velopment of atherosclerosis and hypertension, and 
in kidneys - an increase in the intravascular pressure. 
White adipose tissue functions are performed by the 
secretion of leptin, omentin, adiponectin, resistin, visfa-
tin, apelin, vaspin, hepcidin, chemerin, tumor necrosis 
factor alpha (TNF-a), interleukin 6 (IL-6), monocyte 
chemoattractant protein-1 (MCP-1), and plasminogen 
activator inhibitor-1 (PAI-1), as well as the retinol bind-
ing protein 4 (RBP-4) [1]. In the 1940s a hypothesis was 
established that the interaction between adipose tissue 
and other tissues is bi-directional. A breakthrough came 
in 1994, when Friedman et al. [2] discovered leptin 
produced by mature adipocytes. Currently, adipose 
tissue is considered to be an endocrine organ synthe-
sising adipokines that act in adipose tissue (autocrine 
and paracrine effects) and distant organs and tissues 
(classic endocrine activity) [3, 4]. Visceral adiposity is 
associated with decreased serum adiponectin levels, 
peripheral resistance to insulin, and an increased risk 
of cardio-metabolic complications [5]. Adiponectin was 
also linked with an anti-inflammatory, anti-oxidative, 
and metabolism regulating functions [6, 7]. 
Changes in nutritional status and fat content may 
influence hormonal activity of adipose tissue. The ma-
jority of research has focused on obesity and its impact 
on the adipokine profile [9]. Considerably fewer papers 
focus on the adipokine pattern in respiratory diseas-
es. The following is a review of the literature on the role 
of some adipokines in the pathogenesis and course of 
respiratory diseases in humans and in animal models.
Bronchial asthma
The pathogenic relationship between asthma and obe-
sity in humans is not fully understood. 
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diameter of the peripheral airways; it may also cause 
an increase in the airway hyperresponsiveness. Obese 
patients often have more severe asthma and a partial 
resistance to inhaled glucocorticoids. Better asthma 
It is known that obesity leads to systemic inflam-
mation, resulting in an increase of the concentration of 
adipokines, among others. Obesity adversely affects 
the susceptibility and capacity of the lungs and the 
Table I. Biologically active proteins produced by adipocytes [5]
Adipokine Physiological functions Secretion in obesity Controversies
Energy homeostasis
Leptin
Beneficial effect:
≠ energy expenditure
Ø energy supply
≠
Most obese people are not sensitive to endogenously 
produced leptin
Glucose homeostasis
Adiponectin 
Beneficial effect:
≠ glucose uptake and oxidation
Ø gluconeogenesis
≠ insulin sensitivity
Ø
Disturbed synthesis and secretion of adiponectin  
in obese subjects may lead to the development  
of insulin resistance and type 2 diabetes
Omentin 
Beneficial effect: 
≠ glucose uptake
≠ insulin sensitivity
Ø
Reduced secretion of omentin can be a risk factor for 
metabolic syndrome
Resistin 
Adverse effect:
≠ gluconeogenesis
Ø insulin sensitivity
≠
Resistin can be a factor linking obesity  
with the pathogenesis of type 2 diabetes
Vaspin 
Beneficial effect:
≠ insulin sensitivity
Ø food intake (mechanism not fully understood)
≠
Vaspin plays the role of a compensatory factor  
in the case of increased metabolic complications 
related to obesity
Visfatin
Beneficial effect:
 ≠ glucose uptake
≠ insulin sensitivity
≠
Elevated visfatin levels in obese subjects may be due 
to metabolic changes resulting from the compensatory 
response to developing insulin resistance
Cardiovascular system
Adiponectin 
Beneficial effect:
Ø endothelial adhesion molecules expression
Ø
Hypoadiponectinaemia in obesity does not protect 
the vascular endothelium against inflammatory 
and atherogenic changes; it is a risk factor for 
cardiovascular complications
Apelin 
Beneficial effect:
≠ cardiac contractility
Ø blood pressure
≠
Apelin may have anti-obesity and antidiabetic effects. 
An apelin increase in obesity may be the result  
of inflammation and oxidative stress.
Inflammation
Adiponectin 
Beneficial effect:
Ø TNF-a synthesis and activity and NF-kB activation
Ø
In obesity, adiponectin production decreases, which 
favours the pro-inflammatory effect of TNF-a
Chemerin 
Controversial effect:
Ø production of proinflammatory cytokines (TNF-a, IL-6) 
≠ adiponectin synthesis  
≠ immune cells chemotaxis to areas of inflammation
≠
The chemerin blood concentration increase  
is associated with characteristic features  
of the metabolic syndrome; hence, chemerin  
can serve as a biomarker of this disease.
Omentin 
Beneficial effect:
Ø TNF-a and NF-kB activity
Ø
In obesity, omentin secretion decreases, which favours 
the pro-inflammatory effect of TNF-a
Leptin 
Adverse effect:
≠ production of proinflammatory cytokines (TNF-a, IL-6) 
≠
TNF-a — tumour necrosis factor alpha; IL-6 — interleukin 6; NF-kB — nuclear factor kappa beta
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control occurs after weight reduction in obese pa-
tients [10]. 
Data on the role of adipokines in bronchial asthma 
are, however, often contradictory. 
The concentrations of one of the forms of apelin 
(APE-12) have been evaluated in the serum of healthy 
children and patients with bronchial asthma with nor-
mal body mass as well as in obese patients. 
The mean APE-12 concentrations in obese patients 
both with and without asthma were significantly higher 
than in healthy children, regardless of gender. There 
was no relationship between the adipokine concentra-
tion and the severity of asthma and allergy, spirometric 
parameters, and BMI. Increased APE-12 content in 
obese children suggests that apelin may be involved 
in the pathogenesis of asthma [11]. 
Another study analysed the role of visfatin in 
asthma: serum visfatin concentrations were signifi-
cantly higher in the asthma group compared to healthy 
subjects [12]. 
In a cross-sectional observational study in adults 
with bronchial asthma, Australian clinicians evaluated 
the ratio of resistin to adiponectin as a function of dis-
ease severity, gender, and obesity, and after a 10-week 
weight loss in obese patients. The serum resistin con-
centration and the resistin/adiponectin concentration 
ratio were significantly higher in severe asthma as 
compared to the healthy group, as well as in patients 
with a mild and moderate disease course. In asthma 
patients the resistin concentration was not dependent 
on sex or obesity, while adiponectin levels were lower 
in men compared to women and in obese subjects 
compared to people with a normal BMI. As a result, 
the resistin/adiponectin ratio was significantly higher 
in obese and non-obese men and obese women as 
compared to non-obese women. The authors suggested 
that high resistin concentrations were a predictor of the 
risk of developing severe asthma, while the resistin/adi-
ponectin ratio was a negative predictor of FEV1 in 
patients. Following weight loss, neither the concentra-
tion values of resistin and adiponectin nor the value of 
the resistin/adiponectin ratio were changed. However, 
a change in the body fat percentage was associated with 
a change of the resistin/adiponectin ratio [13].
Other authors also observed that resistin levels are 
significantly elevated in patients with asthma com-
pared to healthy subjects; furthermore, they correlated 
with the severity of the disease [14]. In another study 
it was observed that mean concentrations of resistin 
in non-obese children with atopic asthma were sig-
nificantly higher than in healthy children. After gender 
stratification only obese boys and boys with normal 
body weight had significantly higher serum resistin 
levels than boys in the control group. Girls with obesity 
and with normal weight, as well as girls from the control 
group, showed significantly higher resistin concentra-
tions than boys from the respective groups. There was 
no relationship between adipokine concentrations 
and the severity of asthma and allergies, spirometric 
parameters, and BMI [15]. 
The aim of the study conducted in Portugal was to 
compare the content of leptin and resistin in serum in 
patients with overweight and asthma, in patients with 
a normal body weight, and in obese individuals without 
asthma. Leptin is mainly secreted by adipocytes, and 
serum concentrations directly correlate with adipose 
tissue mass [16]. Although the levels of both adipokines 
were higher in patients with overweight and asthma 
as compared to healthy overweight subjects, these 
differences were not significant. Patients with and 
without asthma and overweight (BMI ≥ 25) and with 
an increased waist circumference showed a higher level 
of leptin [17]. 
In an animal model it was demonstrated that an in-
creased concentration of adiponectin alleviates allergic 
inflammation of the airways and reduces the airway 
hyperresponsiveness. On the other hand, exogenous 
leptin administration causes increased hypersensitiv-
ity. These data — supported by observational studies 
in humans — suggest that a low concentration of 
adiponectin is associated with the risk of developing 
asthma in women and girls during puberty. High 
levels of adiponectin may be associated with a milder 
course of asthma in children and women. In contrast, 
high serum leptin levels are associated with a higher 
incidence and/or severity of asthma, especially in 
women, post-pubescent girls, and boys in the prepu-
bertal period [18]. 
Elevated levels of leptin and reduced levels of adi-
ponectin may be associated with asthma and allergies 
in children. Elevated leptin levels were associated with 
an increased incidence of asthma; this relationship was 
particularly strong in non-atopic asthma. There was no 
relationship between the leptin level and allergic rhino-
conjunctivitis. A low level of adiponectin was associated 
with an increased incidence of atopic dermatitis and 
atopic eczema [19]. 
The relationship between obesity and asthma was 
also evaluated in a prospective study in Finland: after 
analysing data on allergies, smoking, and the levels of 
insulin, CRP, lipids, leptin, and adiponectin, the rela-
tionship between asthma and obesity in adults was con-
firmed. However, the role of leptin and adiponectin in 
the pathogenesis of asthma was not demonstrated [20]. 
In American studies, high levels of serum leptin 
were associated with the occurrence of asthma in adults, 
and it was demonstrated that obesity increases the risk 
of asthma, especially in women [21]. 
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A probable relationship between asthma and obesity 
may be due to the immune modulation of adipokines. In 
men, higher concentrations of adiponectin were as-
sociated with lower levels of exhaled nitric oxide and 
simultaneously with an increased response to the 
bronchodilator [22]. 
Other observations indicate that leptin and adi-
ponectin may be associated with obesity, regardless 
of the occurrence of asthma and its severity: it was 
demonstrated that the mean serum leptin values and 
adiponectin concentrations were similar in patients 
with asthma and in control subjects, but leptin levels 
were higher in women than in men with asthma. The 
value of the leptin/adiponectin concentration ratio 
was significantly higher in women than in men, and it 
positively correlated with the BMI of asthmatic patients 
[23]. French clinicians confirmed the relationship of 
obesity with the coexisting chronic WAT inflammation, 
as well as increased production of TNF-a and IL-6, 
which — through leptin and resistin overproduction- 
may have a pro-inflammatory effect on other organs 
— including lung tissue [24]. 
Chronic obstructive pulmonary disease
Patients with COPD often present with a chronic gen-
eralised inflammation process, as well as malnutrition. 
Elevated serum visfatin levels are observed in some 
inflammatory diseases, but their association with the 
nutritional status and inflammation in COPD remains 
unexplained. In COPD patients, some authors observed 
significantly lower BMI values, as well as a decreased 
adipose tissue volume and an elevated serum visfatin 
concentration compared to the control group. Together 
with increased levels of visfatin, elevated levels of CRP 
and TNF-a were also observed. However, there were 
no significant correlations between the concentration 
of visfatin and BMI or the percentage of adipose tissue 
in both groups [25].
Finnish scientists evaluated the relationship of nes-
fatin and visfatin with inflammation activity, severity of 
symptoms, and lung function in men with emphysema 
and COPD. IL-6, IL-8, TNF-a, and MMP-9 concentra-
tions and exhaled nitric oxide were also measured. The 
measurements were repeated in a subgroup of patients 
after four weeks of treatment with an inhaled cortico-
steroid. Visfatin and nesfatin concentrations correlated 
positively with the IL-6 and TNF-a concentration in the 
blood. In addition, the nesfatin concentration correlated 
positively with the content of IL-8 in the serum of pa-
tients with COPD. Furthermore, visfatin concentration 
correlated negatively with the lung diffusion capacity. 
The adipokine concentration remained unchanged after 
treatment with inhaled corticosteroids [26]. Leptin and 
visfatin have been shown to affect mucus secretion in 
the airways, while resistin intensifies the mucin pro-
duction [27]. 
The leptin concentration in serum of COPD pa-
tients correlated with the patients’ BMI. Alterations 
in the leptin, TNF-a, and prealbumin concentrations 
were observed in episodes of COPD exacerbations; 
however, they did not prove to be reliable markers of 
exacerbations, although the leptin and TNF-a levels 
were significantly higher in patients with exacerba-
tion [28]. In patients with exacerbation, a significant 
positive correlation was also observed between the 
leptin and TNF-a levels, which may be associated with 
an increased overall inflammation [29].
In the meta-analysis of the literature on the role of 
leptin in COPD, attention was drawn to the relationship 
between the leptin concentration and BMI in patients 
with COPD during the disease stability. The correlation 
coefficient was low during exacerbations. A positive 
correlation between the leptin concentration and TNF-
a was found only in exacerbations. Most studies have 
indicated that leptin concentrations in stable COPD 
patients were not significantly different from those in 
the control group, but increased in exacerbations, albeit 
negligibly [30]. 
Attempts to determine the role of leptin in malnu-
trition of COPD patients indicated that leptin was not 
associated with weight loss and there was no significant 
relationship between TNF-a and leptin during the 
energy balance regulation in patients with COPD [31].
Adiponectin appears to be a potent marker of COPD 
exacerbation and of the response to treatment. It was 
demonstrated that serum adiponectin concentrations 
were significantly higher in patients with exacerbation 
of COPD as compared to the control group. A significant 
positive correlation was found between the adiponectin 
and IL-8 levels in patients with COPD, and a negative 
correlation with FEV
1%. 
It was concluded that the measurement of the adi-
ponectin level may be used to assess the severity and 
progression of the disease, and that it may become help-
ful in the stratification of risk and therapy [32]. 
Also, adiponectin levels in induced sputum, signifi-
cantly higher than in healthy subjects, were increased 
in men with exacerbation. Both in the case of exacerba-
tions and in the stable phase, adiponectin levels were 
positively correlated with IL-8 and TNF-a in serum 
and induced sputum. In addition, in exacerbations 
the adiponectin levels depended on the percentage of 
neutrophils in induced sputum [33]. 
In another study, male patients with mild, moderate, 
severe, and very severe COPD with low body weights 
were analysed. Serum concentrations of adiponectin 
were higher in patients with COPD as compared to the 
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control group. At the same time, no significant differ-
ences were found for leptin, IL-1b, TNF-a, and IL-8 in 
the compared groups. Levels of IL-6 and hsCRP were 
higher in the group with mild and moderate COPD 
than in the control group. With an increase in the adi-
ponectin value, a decrease in the BMI and FEV1 values 
was observed [34]. 
Also in Japanese studies, significantly higher values 
of annual decreases of FEV1 correlated positively with 
high values of the serum concentrations of adiponectin 
and negatively with the leptin/adiponectin concentra-
tion ratio. Thus, according to the authors, systematic 
measurements of serum adipokines may be used in 
predicting the deterioration risk in the lung function 
in the COPD course [35].
Lung cancer
Obesity is associated with increased risk of various 
cancers including: breast, renal, colon, corpus uteri, 
and prostate [36]. There are also some signals linking 
lung cancer with adipokines activity. The aim of the 
study carried out in patients suffering from advanced 
non-small cell lung cancer was to estimate cancer ca-
chexia with regard to the concentration of resistin and 
leptin. The evaluation of resistin and leptin concentra-
tions in patients with advanced cancer, not treated 
previously with chemotherapy, showed significantly 
higher levels of resistin and lower levels of leptin in 
comparison to healthy individuals. Although leptin 
and resistin may play an important pro-inflammatory 
role in the cancer cachexia pathogenesis, their use 
as diagnostic or prognostic markers requires further 
research [37]. 
There is no conclusive evidence so far for the un-
disputed contribution of adipocytokines in cachexia 
development in advanced lung cancer [38].
However, there is evidence of the involvement of 
some adipocytokines in the development and progres-
sion of cancer. A correlation between the levels of leptin, 
adiponectin, as well as resistin and the nutritional sta-
tus, and systemic inflammation in the course of cancer 
and in its terminal stage was observed. 
The potential prognostic significance of these 
adipokines was demonstrated, as well. Adiponectin is 
the most commonly present adipokine in the tumour 
microenvironment, but its role in tumour progression 
remains unspecified. Using tumour cell lines, the effect 
of adiponectin on migration and invasion in non-small 
cell lung cancer was evaluated. The presence of adipo-
nectin in the cancer cell environment inhibited their 
migratory and invasive abilities. Exogenous adiponectin 
significantly interfered with the migration and invasive 
capacity of cancer cells, suggesting that adiponectin 
could be an innovative form of therapy in non-small 
cell lung cancer [39]. 
Japanese clinicians assessed the relationship be-
tween the adiponectin levels and the presence of 
non-haematological adverse reactions in advanced 
non-small cell lung cancer after treatment with epider-
mal growth factor receptor tyrosine kinase inhibitors 
(EGFR-TKIs). Treatment with EGFR-TKIs affects the 
adiponectin level. The initial adiponectin level (at the 
time of diagnosis) influences adverse events caused by 
EGFR-TKIs [40].  
A growing percentage of obese people in the popu-
lation and the accompanying cancer risk increased the 
need to understand the pathogenesis of this relation, 
e.g. by the analysis of the molecular pathways activated 
by adiponectin and leptin. Adipokine deregulation in 
obesity and its influence on tumour progression and 
metastasis has become one of the areas of such research: 
altered levels of adipokines or altered expression of 
adipokine receptors in cancer can lead to disorders in 
further molecular pathways. Leptin and adiponectin 
generally cause opposite molecular effects: the relation-
ship between an increased serum leptin concentration 
and tumour growth has been highlighted in epidemio-
logical studies, while adiponectin may have inhibitory 
effects on tumour growth [41].
Pulmonary arterial hypertension
Apelin and adiponectin play a role in the regulation of 
homeostasis of the endothelium and smooth muscle 
cells. Apelin modulates endothelial nitric oxide synthase 
(eNOS) expression, induces eNOS-dependent vasodi-
latation, counteracts angiotensin-II mediated vasocon-
striction, and has positive inotropic and cardioprotec-
tive effects [42]. Apelin and adiponectin are highly 
expressed in pulmonary vessels, but their function is 
not entirely clear. The participation of adipocytokines in 
the pulmonary arterial hypertension pathogenesis still 
needs to be clarified, although interesting observations 
have been made about the ELA protein (Elabela/Tod-
dler), i.e. an endogenous apelin receptor agonist in the 
cardiovascular system of adults. 
The goal of animal studies on rats was to find evi-
dence of the contribution of this protein in the patho-
genesis of pulmonary hypertension and to demonstrate 
the alleviation of hypertension symptoms as a result of 
the exogenous administration of ELA. The subcutane-
ous ELA protein administration reduced the systolic 
pressure in the pulmonary artery, decreased the right 
ventricular hypertrophy, and reduced the intensity of 
pulmonary remodelling in rats. The results of these 
studies indicate the beneficial effect of ELA protein 
on the inhibition of cardio-pulmonary remodelling in 
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laboratory animals. Furthermore, they may be indica-
tive of potential new possibilities of seeking effective 
therapies in people suffering from various forms of 
pulmonary hypertension [43] The apelin and adipo-
nectin expression in pulmonary vessels is regulated 
by factors involved in the pathogenesis of PAH and is 
suppressed in the endothelial cells of pulmonary arter-
ies in patients with PAH. Apelin has, therefore, been 
proposed as a potential biomarker for PAH [42]. The 
above conclusions are also confirmed by the observa-
tions of other authors [44]. 
It has been hypothesised that the signalling disrup-
tion of the apelin — adiponectin axis leads to increased 
vascular remodelling in PAH. It was found that mice 
exposed to chronic hypoxia and deprived of apelin 
developed more severe PAH symptoms compared to 
wild-type mice. A micro CT scan of the pulmonary 
arteries showed a significant reduction in microvas-
cularisation in apelin-depleted mice; they also had 
a significantly reduced level of serum nitrates. In PAH 
patients, the levels of apelin were significantly lower 
than in the control group. These data show that the 
apelin-adiponectin axis disruption may exacerbate PAH 
and identify this pathway as a potentially important 
therapeutic target [44].
Inflammations in the respiratory system
The secretion of resistin and visfatin is increased during 
inflammation as a response to proinflammatory cyto-
kines. Resin and visfatin may also contribute to inflam-
matory processes, triggering cytokine production, and 
thus may be an attractive target for new therapeutic 
strategies in inflammatory diseases of the respiratory 
system chronic [45]. 
In all patients with community-acquired pneumonia, 
both those who survived and those who died, it has 
been demonstrated that the visfatin concentration was 
significantly increased compared to the control group; 
visfatin has been recognised as an independent prognos-
tic factor in determining the risk of death during 30 days 
of observation. Increased visfatin concentrations also 
correlated with the disease severity and other inflam-
matory markers [46]. 
The aim of a team of Polish transplantologists was 
to examine the concentrations of visfatin, irisin, and 
omentin in patients with end-stage lung disease (cystic 
fibrosis, COPD, and idiopathic pulmonary fibrosis) 
before and after lung transplantation. The omentin 
concentration significantly decreased within three days 
of transplantation, whereas the visfatin concentration 
dropped later, 30 days after the procedure. An effective 
lung transplant surgery contributes to the improve-
ment of the impaired lung function parameters and 
to the inhibition of the ongoing inflammatory process 
leading to changes in the serum concentration of adipo-
kines. Lowered levels of both adipokines persisted for 
a further two months. The irisin concentration did not 
change before or after the transplantation. An immu-
nosuppressive therapy did not affect the levels of the 
analysed adipokines; however, its effect on the omentin 
and visfatin concentration cannot be excluded [47].
Conclusion
The role of adipocytokines in good health as well as 
in the context of four respiratory diseases: bronchial 
asthma, COPD, pneumonia, and cancer, was analysed. 
Further research is needed to clarify the functional — au-
tocrine and/or paracrine — effects of adipocytokines in 
homeostasis and disease. There is also a need for further 
studies devoted to the mechanisms of their effect on 
respiratory diseases. It is crucial to distinguish the effects 
of adipokines in acute and chronic diseases, because 
there may be a slightly different impact and significance 
depending on the severity of the disease process.
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